Bevacizumab

CLINICAL USE


Treatment of metastatic carcinoma of the colon or rectum

DOSE IN NORMAL RENAL FUNCTION

5 mg/kg every 14 days

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :149 000
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :No data
  • %Excreted unchanged in urine &nbsp &nbsp : No data

  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :0.046

  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :11–50 days (average 20 days)

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Use with caution
  • 10 to 20 &nbsp &nbsp : Use with caution
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Use with caution

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Use with caution. See ‘Other Information’

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Use with caution. See ‘Other Information’
  • HDF/high flux &nbsp :Not dialysed. Use with caution. See ‘Other Information’
  • CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Use with caution. See ‘Other Information’

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsNone known

    ADMINISTRATION

    Reconstition

    –

    Route

    IV infusion

    Rate of Administration

    30–90 minutes depending on how the patient tolerates it

    Comments

    Dilute in 100 mL of sodium chloride 0.9% DO NOT mix with glucose solutions

    OTHER INFORMATION

  • Increased incidence of hypertension has been seen with treatment
  • People with a history of hypertension may be at an increased risk of proteinuria.
  • Discontinue therapy in patients with Grade 4 proteinuria (nephrotic syndrome)
  • Can delay wound healing Bevacizumab has been used in a haemodialysis patient at a dose of 5 mg/kg every 14 days.
    Tags:

    • Related News

    sotalol hydrochloride.txt

    tazocin.txt